KRAS and colorectal cancer: We first focussed on the RAS/MAPK pathway as mutations in K‐Ras have been linked to resistance to everolimus in colorectal cancer (Di Nicolantonio et al., 2010), and genetic perturbations in the Ras/MAPK pathway have been documented in BTC (Li et al., 2014).